AbbVie snubs Galapagos, takes own JAK-1 into Phase III

AbbVie Inc. (NYSE:ABBV) declined to exercise its option to license Janus kinase-1 (JAK-1) inhibitor filgotinib ( GLPG0634) from Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) and said it would begin Phase III testing by YE15 on ABT-494, its own selective JAK-1 inhibitor to treat rheumatoid arthritis (RA).

Galapagos

Read the full 457 word article

How to gain access

Continue reading with a
two-week free trial.